DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19 01.31-2021 Health News Comments Off on DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19
Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio 02.09-2020 Medications Comments Off on Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio